MANUFACTURING ARTICLES

  • Engineering RNA Agonists For Systemic Immunity Without Systemic Toxicity

    Krieg believes the answer lies in a deeper understanding of innate immune biology and the design of RNA/DNA hybrid mimics of viral RNA and DNA that are detected by innate immune receptors.

  • Is mRNA Manufacturing Overbuilt?

    mRNA pipelines continue to advance, but has provider growth outpaced the pipeline? Let's take a closer look.

  • What Oligo Manufacturing Risks Are We Underestimating?

    Earlier this year, I attended the OPT Congress, where I had the great fortune of meeting consultant Marc Lemaitre. I recently sat down with Lemaitre for a follow-up interview to gauge some of the evolutions he’s been watching within the CMC landscape for oligo development. Here, he digs into the shifts in quality he’s noted, pointing out some of the potential pitfalls we may encounter in our manufacturing that could stand to impact the overall quality of our oligos. 

  • RNA Oligonucleotide Synthesis: How Advanced Manufacturing Technologies Are Accelerating Innovation

    From a tech perspective, the manufacturing objective is shifting toward integrated process optimization. Automated reaction control, multivariate analytics, and more can connect molecular quality with operational performance. 

  • What Baby KJ Taught Us About mRNA COGS

    Here, in part 2 of this three-part series, I share a few details that came to light about the COGS behind Baby KJ’s therapy production. Obviously, we know why it’s important to keep these figures in mind as we move forward; but I particularly liked Strauss’ reminder that it’s our job to “think systematically about how we’re going to create a safety net of sustainable, accessible product that can be widely distributed at an affordable cost.”

  • Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics

    RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.

MANUFACTURING VIDEOS

The innovative MYCAP bottle closure system provides more options for aseptic fluid transfer in bottles and rigid containers. The elastomeric closure makes it a truly universal closure system.

Explore the evolving oligo therapeutic landscape while identifying common challenges of bringing production in‑house and the key factors that shape long‑term success for smoother scale‑up.

Dive into this overview of vaccine development and learn how to overcome some key challenges with Precision NanoSystems Inc.'s field application scientist, Dr. Ian Villamagna.

CMC Consultant Sujit Jain and NanoVation CEO Dominik Witzigmann share their perspectives on the manufacturing technology advancements that have and will continue to meaningfully improve passive delivery of mRNA-LNPs.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS